GlassScriptPhysician profile
Minesh Nandi
NPI 1306376421
$7,026.38
in general payments reported to CMS, 2019-2025
55 companies · $4,569 in 2025
The $4,569 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $379 · 2024: $2,078 · 2025: $4,569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,402 · Long Term Medical Supply Or Device Loan: $1,097 · Education: $528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,401.65 |
| Long Term Medical Supply Or Device Loan | $1,096.70 |
| Education | $528.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,488.30 | 2023-2025 | |
| Pfizer INC. | $588.96 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $445.23 | 2024-2025 | Enhertu, Lynparza, Tagrisso |
| Merck Sharp & Dohme LLC | $330.16 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Sobi, INC | $307.73 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $278.63 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| E.R. Squibb & Sons, L.L.C. | $205.45 | 2023-2025 | Opdivo, Opdualag, Augtyro |
| Incyte Corporation | $198.02 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Genzyme Corporation | $176.78 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $166.20 | 2024-2025 | |
| Daiichi Sankyo INC. | $163.99 | 2024-2025 | Enhertu, Vanflyta, Injectafer |
| Legend Biotech USA INC. | $162.92 | 2024-2025 | Carvykti |
| Glaxosmithkline, LLC. | $160.46 | 2023-2025 | Ojjaara, Blenrep, Zejula |
| Eisai INC. | $142.59 | 2023-2025 | |
| Abbvie INC. | $126.19 | 2023-2025 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $125.13 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Bayer Healthcare Pharmaceuticals INC. | $124.61 | 2023-2025 | |
| Secura Bio, INC. | $122.63 | 2025 | Copiktra |
| Caris Mpi, INC. | $116.10 | 2025 | Mi Cancer Seek |
| Seagen INC. | $114.64 | 2023-2024 | Padcev |
| Gilead Sciences, INC. | $90.11 | 2023-2025 | Trodelvy |
| Puma Biotechnology, INC. | $88.33 | 2024-2025 | |
| Stemline Therapeutics INC. | $78.95 | 2025 | Orserdu |
| Janssen Biotech, INC. | $78.62 | 2024-2025 | Erleada, Darzalex, Rybrevant |
| Pharmaessentia USA Corporation | $76.91 | 2025 | Besremi |
| Genentech USA, INC. | $76.79 | 2023-2025 | Tecentriq, Columvi, Gazyva |
| Astellas Pharma US INC | $76.70 | 2023-2024 | Padcev |
| Lilly USA, LLC | $72.38 | 2024 | Verzenio, Jaypirca, Retevmo |
| Deciphera Pharmaceuticals INC. | $70.52 | 2025 | Qinlock, Romvimza, Tgct |
| Beone Medicines USA, INC. | $69.50 | 2025 | Brukinsa |
| Celgene Corporation | $62.72 | 2023-2024 | Reblozyl, Pomalyst |
| Blueprint Medicines Corporation | $51.22 | 2024-2025 | Ayvakit |
| Tersera Therapeutics LLC | $49.03 | 2023-2025 | Xermelo, Zoladex |
| Exelixis INC. | $46.87 | 2024 | Cabometyx |
| Novocure INC. | $40.58 | 2024 | Optune |
| Takeda Pharmaceuticals U.S.A., INC. | $39.23 | 2025 | Iclusig |
| Beigene USA, INC. | $38.72 | 2024-2025 | Tevimbra, Brukinsa |
| Servier Pharmaceuticals LLC | $38.47 | 2024-2025 | |
| Springworks Therapeutics, INC. | $34.42 | 2025 | Ogsiveo |
| Agios Pharmaceuticals, INC. | $26.93 | 2025 | Pyrukynd |
| Nuvation Bio INC. | $25.67 | 2025 | Ibtrozi |
| Regeneron Healthcare Solutions, INC. | $22.29 | 2025 | Libtayo |
| Emd Serono, INC. | $21.62 | 2025 | |
| Taiho Oncology, INC. | $21.41 | 2024 | |
| Tempus Ai, INC | $20.89 | 2025 | Xt Cdx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.46 | 2025 | |
| Adaptive Biotechnologies Corporation | $18.18 | 2024 | Clonoseq |
| Mirati Therapeutics, INC. | $17.27 | 2024 | Krazati |
| Janssen Pharmaceuticals, INC | $16.85 | 2024 | Xarelto |
| Genmab U.S., INC. | $16.83 | 2024 | Epkinly |
| Morphosys, US INC. | $16.65 | 2024 | Monjuvi |
| Karyopharm Therapeutics INC. | $16.15 | 2024 | Xpovio |
| Organon LLC | $14.87 | 2024 | |
| Sumitomo Pharma America, INC. | $14.45 | 2024 | Orgovyx |
| Spectrum Pharmaceuticals INC. | $13.07 | 2023 | Rolvedon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minesh Nandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.